Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01) by 300 percent. This is a 80.95 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $207.705 million which beat the analyst consensus estimate of $192.918 million by 7.67 percent. This is a 38.63 percent increase over sales of $149.824 million the same period last year.